Literature DB >> 32808727

APOE and dementia - resequencing and genotyping in 105,597 individuals.

Katrine L Rasmussen1,2, Anne Tybjaerg-Hansen1,2,3,4, Børge G Nordestgaard2,3,4,5, Ruth Frikke-Schmidt1,2,4.   

Abstract

INTRODUCTION: The mechanism behind the strong association between the ɛ2/ɛ3/ɛ4 apolipoprotein E gene (APOE) polymorphism and Alzheimer's disease is not well-characterized. Because low plasma levels of apoE associate with risk of dementia, genetic variants altering apoE levels in general may also associate with dementia.
METHODS: The APOE gene was sequenced in 10,369 individuals, and nine amino acid-changing variants with frequencies ≥2/10,000 were further genotyped in 95,228 individuals. Plasma apoE levels were measured directly.
RESULTS: Risk of all dementia and Alzheimer's disease (AD) increased with decreasing genetically determined apoE levels (P = 5 × 10-4 and P = 1 × 10-4 after APOE ɛ2/ɛ3/ɛ4 adjustment). Hazard ratios (95% confidence intervals) for all dementia and AD were 2.76 (1.39 to 5.47) and 4.92 (2.36 to 10.29) for the group with the genetically lowest apoE versus ɛ33. DISCUSSION: We found that genetically low apoE levels increase and genetically high levels decrease risk, beyond ɛ2/ɛ3/ɛ4. This underscores that dementia risk more likely relates to variants affecting levels of apoE.
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.

Entities:  

Keywords:  APOE; Alzheimer's disease; apolipoprotein E; dementia; genetics; rare variation

Year:  2020        PMID: 32808727     DOI: 10.1002/alz.12165

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  9 in total

Review 1.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

2.  Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.

Authors:  Yann Le Guen; Michael E Belloy; Benjamin Grenier-Boley; Itziar de Rojas; Atahualpa Castillo-Morales; Iris Jansen; Aude Nicolas; Céline Bellenguez; Carolina Dalmasso; Fahri Küçükali; Sarah J Eger; Katrine Laura Rasmussen; Jesper Qvist Thomassen; Jean-François Deleuze; Zihuai He; Valerio Napolioni; Philippe Amouyel; Frank Jessen; Patrick G Kehoe; Cornelia van Duijn; Magda Tsolaki; Pascual Sánchez-Juan; Kristel Sleegers; Martin Ingelsson; Giacomina Rossi; Mikko Hiltunen; Rebecca Sims; Wiesje M van der Flier; Alfredo Ramirez; Ole A Andreassen; Ruth Frikke-Schmidt; Julie Williams; Agustín Ruiz; Jean-Charles Lambert; Michael D Greicius; Beatrice Arosio; Luisa Benussi; Anne Boland; Barbara Borroni; Paolo Caffarra; Delphine Daian; Antonio Daniele; Stéphanie Debette; Carole Dufouil; Emrah Düzel; Daniela Galimberti; Vilmantas Giedraitis; Timo Grimmer; Caroline Graff; Edna Grünblatt; Olivier Hanon; Lucrezia Hausner; Stefanie Heilmann-Heimbach; Henne Holstege; Jakub Hort; Deckert Jürgen; Teemu Kuulasmaa; Aad van der Lugt; Carlo Masullo; Patrizia Mecocci; Shima Mehrabian; Alexandre de Mendonça; Susanne Moebus; Benedetta Nacmias; Gael Nicolas; Robert Olaso; Goran Papenberg; Lucilla Parnetti; Florence Pasquier; Oliver Peters; Yolande A L Pijnenburg; Julius Popp; Innocenzo Rainero; Inez Ramakers; Steffi Riedel-Heller; Nikolaos Scarmeas; Philip Scheltens; Norbert Scherbaum; Anja Schneider; Davide Seripa; Hilkka Soininen; Vincenzo Solfrizzi; Gianfranco Spalletta; Alessio Squassina; John van Swieten; Thomas J Tegos; Lucio Tremolizzo; Frans Verhey; Martin Vyhnalek; Jens Wiltfang; Mercè Boada; Pablo García-González; Raquel Puerta; Luis M Real; Victoria Álvarez; María J Bullido; Jordi Clarimon; José María García-Alberca; Pablo Mir; Fermin Moreno; Pau Pastor; Gerard Piñol-Ripoll; Laura Molina-Porcel; Jordi Pérez-Tur; Eloy Rodríguez-Rodríguez; Jose Luís Royo; Raquel Sánchez-Valle; Martin Dichgans; Dan Rujescu
Journal:  JAMA Neurol       Date:  2022-07-01       Impact factor: 29.907

3.  APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia.

Authors:  Yara Abou Khalil; Oriane Marmontel; Jean Ferrières; François Paillard; Cécile Yelnik; Valérie Carreau; Sybil Charrière; Eric Bruckert; Antonio Gallo; Philippe Giral; Anne Philippi; Olivier Bluteau; Catherine Boileau; Marianne Abifadel; Mathilde Di-Filippo; Alain Carrié; Jean-Pierre Rabès; Mathilde Varret
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

4.  Association of DNA methylation and genetic variations of the APOE gene with the risk of diabetic dyslipidemia.

Authors:  Suheir Ereqat; Stéphane Cauchi; Khaled Eweidat; Muawiyah Elqadi; Manal Ghatass; Anas Sabarneh; Abedelmajeed Nasereddin
Journal:  Biomed Rep       Date:  2022-05-27

5.  APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia.

Authors:  Chia-Chen Liu; Melissa E Murray; Xia Li; Na Zhao; Na Wang; Michael G Heckman; Francis Shue; Yuka Martens; Yonghe Li; Ana-Caroline Raulin; Cassandra L Rosenberg; Sydney V Doss; Jing Zhao; Melissa C Wren; Lin Jia; Yingxue Ren; Tadafumi C Ikezu; Wenyan Lu; Yuan Fu; Thomas Caulfield; Zachary A Trottier; Joshua Knight; Yixing Chen; Cynthia Linares; Xue Wang; Aishe Kurti; Yan W Asmann; Zbigniew K Wszolek; Glenn E Smith; Prashanthi Vemuri; Kejal Kantarci; David S Knopman; Val J Lowe; Clifford R Jack; Joseph E Parisi; Tanis J Ferman; Bradley F Boeve; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; John D Fryer; Hu Wang; Xianlin Han; Carl Frieden; Dennis W Dickson; Owen A Ross; Guojun Bu
Journal:  Sci Transl Med       Date:  2021-09-29       Impact factor: 19.319

6.  Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping.

Authors:  Michael E Belloy; Sarah J Eger; Yann Le Guen; Vincent Damotte; Shahzad Ahmad; M Arfan Ikram; Alfredo Ramirez; Anthoula C Tsolaki; Giacomina Rossi; Iris E Jansen; Itziar de Rojas; Kayenat Parveen; Kristel Sleegers; Martin Ingelsson; Mikko Hiltunen; Najaf Amin; Ole Andreassen; Pascual Sánchez-Juan; Patrick Kehoe; Philippe Amouyel; Rebecca Sims; Ruth Frikke-Schmidt; Wiesje M van der Flier; Jean-Charles Lambert; Zihuai He; Summer S Han; Valerio Napolioni; Michael D Greicius
Journal:  Alzheimers Res Ther       Date:  2022-02-04       Impact factor: 6.982

7.  Severe COVID-19 in Alzheimer's disease: APOE4's fault again?

Authors:  Nian Xiong; Martin R Schiller; Jingwen Li; Xiaowu Chen; Zhicheng Lin
Journal:  Alzheimers Res Ther       Date:  2021-06-12       Impact factor: 6.982

8.  Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.

Authors:  Joni V Lindbohm; Nina Mars; Keenan A Walker; Archana Singh-Manoux; Gill Livingston; Eric J Brunner; Pyry N Sipilä; Kalle Saksela; Jane E Ferrie; Ruth C Lovering; Stephen A Williams; Aroon D Hingorani; Rebecca F Gottesman; Henrik Zetterberg; Mika Kivimäki
Journal:  Alzheimers Dement       Date:  2021-08-02       Impact factor: 16.655

Review 9.  APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.

Authors:  Zonghua Li; Francis Shue; Na Zhao; Mitsuru Shinohara; Guojun Bu
Journal:  Mol Neurodegener       Date:  2020-11-04       Impact factor: 18.879

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.